The global shift towards personalized medicine and advanced cell therapies demands analytical tools that can provide high-resolution, non-destructive insights into biological processes. Regulatory bodies are increasingly scrutinizing the quality and safety of cell-based products, driving demand for robust, real-time monitoring solutions. This technology offers a competitive edge by enabling faster, more reliable data acquisition, reducing experimental variability, and accelerating time-to-market for novel therapeutics and diagnostic assays.
Enables Non-Invasive, High-Precision Analysis: Acquires autofluorescence and reflected light simultaneously without damaging samples, allowing detailed analysis of cell and tissue physiological states. This enables long-term observation and reuse of valuable samples.
Integrates with Spatial Information: Correlates acquired autofluorescence and reflected light data with specific spatial coordinates, providing clear understanding of changes occurring at specific locations within cells or tissues for deeper insights.
Establishes Strong IP-Based Advantage: Secures a robust competitive advantage with 22 claims, registered after overcoming rigorous examination against 13 prior art documents, establishing clear differentiation for adopting enterprises.
The technical superiority and robustness of this patent are objectively proven by overcoming rigorous examination against 13 prior art documents and subsequent rejections. With 22 broad claims, the patent protects the entire system combining multiple elemental technologies. Its registration after overcoming an office action indicates a clear and robust scope, less susceptible to invalidation, further supported by involvement of a prominent patent law firm.
This patent primarily covers the system for non-invasive data acquisition and spatial correlation. White space exists in developing advanced AI/ML algorithms for predictive modeling based on the acquired data, or integrating this system with microfluidic devices for high-throughput, automated cell culture analysis.
Implementing this technology could reduce re-experiments through non-invasive analysis and shorten analysis time via high-precision spatial information. For example, in a new drug development process, assuming annual labor costs for 10 researchers at ~$65K/person (AI est.) (total ~$650K (AI est.)) and annual consumables/reagent costs of ~$330K (AI est.). A 20% reduction in analysis time could save ~$130K (AI est.) in labor costs, and a 15% reduction in consumables due to fewer re-experiments could save ~$50K (AI est.). This totals an estimated annual cost reduction of ~$180K (AI est.).
X: Analysis Data Acquisition Efficiency
Y: Sample Non-Invasiveness